This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pylera

Allergan plc

Drug Names(s): Helizide

Description: Each Pylera capsule contains biskalcitrate potassium (140 mg), metronidazole (125 mg) and tetracycline hydrochloride (125 mg). The U.S. patent on the Pylera capsule technology expires in December 2018.

Metronidazole is a nitroimidazole antibiotic drug used in the treamtent of infections caused by susceptible organisms particularly anaerobic bacteria and protozoa. It is marketed by Sanofi-Aventis under the trade name Flagyl, and also by various generic manufacturers. It exerts its effects by interfering with DNA synthesis.

Tetracycline is a broad-spectrum antibiotic produced by the streptomyces bacterium, indicated for use against many bacterial infections. Tetracycline inhibits bacterial cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents protein synthesis.

Deal Structure: In November 2007, Axcan Pharma announced that it entered into an agreement for Axcan to be acquired by TPG Capital and its affiliates in an all-cash transaction with a total value of approximately US$1.3 billion.

NewBridge and Pylera
In July 2009, NewBridge entered into an exclusive license and supply agreement with Axcan Pharma for Pylera, an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Pursuant to the agreement, NewBridge is entitled to obtain exclusive rights in certain markets where it obtains required regulatory approvals and launches the product.

Aptalis and NovaMedica
In December 2013, NovaMedica signed a partnership agreement with Aptalis to develop and commercialize a portfolio of three of Aptalis Pharmas gastrointestinal pharmaceutical products in Russia, including Pylera. Under the agreement, NovaMedica will work towards to...See full deal structure in Biomedtracker

Partners: NewBridge Pharmaceuticals NovaMedica LLC


Pylera News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug